Probiotics for pancreatic β-cell function: from possible mechanism of action to assessment of effectiveness

Abstract

Type 2 diabetes (T2D) is a metabolic disease characterized by chronic hyperglycemia because of insulin resistance (IR) and\or pancreatic β-cell dysfunction. Last century research showed that gut microbiota has a direct effect on metabolism and metabolic diseases. New studies into the human microbiome and its connection with the host is making it possible to develop new therapies for a wide variety of diseases. Inflammation is a well-known precursor to metabolic syndrome, which increases the risk of hypertension, visceral obesity, and dyslipidemia, which can lead to T2D through the damage of pancreatic β-cell and reduce insulin secretion. Current understanding for beneficial effects of probiotics in T2D strictly rely on both animal and clinical data, which mostly focused on their impact on IR, anthropometric parameters, glycemic control and markers of chronic systemic inflammation. From the other hand, there is a lack of evidence-based probiotic efficacy on pancreatic β-cell function in terms of T2D and related metabolic disorders. Therefore, current review will focus on the efficacy of probiotics for the protection of β-cells damage and it`s mechanism in patients with T2D.

Keywords:

• β-cells damage
• β-cells dysfunction
• Bifidobacterium
• Lactobacillus
• multi-strain probiotic
• Akkermansia muciniphila
• type 2 diabetes
• probiotic

Author contributions

M. Khomenko, T. Falalyeyeva and N. Kobyliak wrote the manuscript, created figures and tables. A. Fedchenko, O. Savchuk, L. Ostapchenko and Y. Tseyslyer, supervised and revised the manuscript.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Additional information

Funding

This research received no external funding.